|
|
|
@ -38,5 +38,7 @@
|
|
|
|
|
- Dosing strategies for Ivermectine are being revisited
|
|
|
|
|
- The fix-dose coformulation of Albendazole/Ivermectine is [[due]] to enter regulatory agencies
|
|
|
|
|
- Acceptability and safety studies are underway
|
|
|
|
|
-
|
|
|
|
|
- The access plan is being developed
|
|
|
|
|
- Integration across programs (these results have implications beyond STH)
|
|
|
|
|
- Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal.
|
|
|
|
|
-
|